Skip to main content
Premium Trial:

Request an Annual Quote

Keeping Up With Flatley

Illumina CEO Jay Flatley tells Xconomy's Luke Timmerman that for a long time there was no innovation in the industry until the advent of next-gen sequencing which caused "huge amount of money" to be invested in the space. Currently, Flatley considers Life Technologies to be Illumina's primary competitor, but says his company is "way ahead" in terms of market share. However, there are also a few upstarts, such as Complete Genomics, who are encroaching on part of the market Illumina considers to be its own. As for when the $1,000 genome will materialize, Flatley says that "if you count bioinformatics, if you count sample prep, if you count data storage in the number, if you count it all, then it's somewhere in the three to five-year timeframe. ... The sequencing will get there faster than that."

The Scan

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.

Team Presents Cattle Genotype-Tissue Expression Atlas

Using RNA sequences representing thousands of cattle samples, researchers looked at relationships between cattle genotype and tissue expression in Nature Genetics.

Researchers Map Recombination in Khoe-San Population

With whole-genome sequences for dozens of individuals from the Nama population, researchers saw in Genome Biology fine-scale recombination patterns that clustered outside of other populations.

Myotonic Dystrophy Repeat Detected in Family Genome Sequencing Analysis

While sequencing individuals from a multi-generation family, researchers identified a myotonic dystrophy type 2-related short tandem repeat in the European Journal of Human Genetics.